<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02903927</url>
  </required_header>
  <id_info>
    <org_study_id>CT LUCIA 601PY BER 401-14</org_study_id>
    <nct_id>NCT02903927</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate the Visual Performance of Two Monofocal Intraocular Lenses</brief_title>
  <acronym>LUCIOL</acronym>
  <official_title>Prospective Comparative Randomized Clinical Trial to Evaluate the Visual Performance of Two Monofocal Intraocular Lenses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carl Zeiss Meditec AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Carl Zeiss Meditec AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the clinical study is to evaluate the performance of the CT LUCIA 601&#xD;
      PY for the monocular uncorrected distance visual acuity and compare it to the reference&#xD;
      monofocal IOL Acrysof IQ SN60WF.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 20, 2014</start_date>
  <completion_date type="Actual">October 10, 2016</completion_date>
  <primary_completion_date type="Actual">June 6, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Uncorrected distance visual acuity (UCVA) (monocular)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Catartact</condition>
  <arm_group>
    <arm_group_label>CT LUCIA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Acrysof IQ Sn60WF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Implantation of CT LUCIA IOL</intervention_name>
    <arm_group_label>CT LUCIA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Implantation of Acrysof IQ SN60WF IOL</intervention_name>
    <arm_group_label>Acrysof IQ Sn60WF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient informed of the consequences and constraints of the protocol and who has given&#xD;
             his/her written informed consent;&#xD;
&#xD;
          -  Patients of any gender, aged 50 to 90 years;&#xD;
&#xD;
          -  Senile cataract in at least 1 eye;&#xD;
&#xD;
          -  Assured follow-up examinations;&#xD;
&#xD;
          -  Healthy eyes besides clinically significant cataract&#xD;
&#xD;
          -  Biometry measurement/cataract density compatible with the IOLMaster evaluation.&#xD;
&#xD;
        Post-operative inclusion criteria:&#xD;
&#xD;
          -  IOL implanted in the capsular bag;&#xD;
&#xD;
          -  The IOL model (CT LUCIA 601PY or Acrysof IQ SN60WF) has been implanted;&#xD;
&#xD;
          -  No intraoperative complications; no damaged capsular bag, no intraocular hemorrhage;&#xD;
             no can opener rhexis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  â€¢ Patients unable to meet the limitations of the protocol or likely of non-cooperation&#xD;
             during the trial;&#xD;
&#xD;
               -  Patients whose freedom is impaired by administrative or legal order;&#xD;
&#xD;
               -  Current participation in another drug or device investigation;&#xD;
&#xD;
               -  Allergy to heparin&#xD;
&#xD;
               -  Monophthalmic patient&#xD;
&#xD;
               -  Ocular disorders, other than cataract, that could potentially cause future acuity&#xD;
                  loss to a level of 0.20 logMAR (best-corrected) or worse the operated eye&#xD;
&#xD;
               -  Any anterior segment pathology that could significantly affect outcomes (e.g.&#xD;
                  chronic uveitis, iritis, corneal dystrophy, etc.)&#xD;
&#xD;
               -  Diabetic retinopathy&#xD;
&#xD;
               -  Traumatic cataract&#xD;
&#xD;
               -  Aniridia&#xD;
&#xD;
               -  Microphthalmus&#xD;
&#xD;
               -  Amblyopia&#xD;
&#xD;
               -  Degenerative visual disorders (e.g. macular degeneration, optic nerve atrophy, or&#xD;
                  retinal disorders)&#xD;
&#xD;
               -  Patient expected to require retinal laser treatment before the end of the&#xD;
                  follow-up&#xD;
&#xD;
               -  Previous intraocular and corneal surgery&#xD;
&#xD;
               -  Expected postop. astigmatism greater than 1 D&#xD;
&#xD;
               -  Any type of corneal disorder&#xD;
&#xD;
               -  Dementia&#xD;
&#xD;
               -  Diabetes mellitus&#xD;
&#xD;
               -  Pseudoexfoliation syndrome (PXF)&#xD;
&#xD;
               -  Glaucoma or IOP higher than 24mmHg under ocular hypertension treatment&#xD;
&#xD;
               -  Any other pathology or condition presenting, according to the investigator&#xD;
                  opinion, a risk for the patient&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>September 9, 2016</study_first_submitted>
  <study_first_submitted_qc>September 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2016</study_first_posted>
  <last_update_submitted>January 25, 2018</last_update_submitted>
  <last_update_submitted_qc>January 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

